Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:27:42.102Z.
Consensus retrieved: 2026-10-06T14:22:09.087Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:27:42.102Z.
Quote observation: 2026-10-06T18:23:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f972cfcdde9e4531ce3198b66662ffcb9080d57c966754dbe52ec7edaf14096
FORWARD PE RATIO
N/A
NervGen Pharma Corp. Common stock
Market Cap
$148.36M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $148.36M | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $148.48M | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.69M | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.74M | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.94M | N/A |
| Codexis, Inc. (CDXS)vs › | $149.51M | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.67M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $150.43M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.18M | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $143.75M | 7.16 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in CAD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
